Behavioral Weight Loss Intervention + Cardiac Rehab for Atrial Fibrillation and Obesity
(BeWEL IN CR-AF Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether combining weight-loss classes with cardiac rehab can help individuals with both atrial fibrillation (a heart rhythm problem) and obesity feel better and potentially correct their heart rhythm. The focus is on whether losing at least 10% of body weight can improve symptoms for those with both conditions. Participants will either engage in traditional cardiac rehab or the same rehab plus weight-loss classes (Behavioral Weight Loss Therapy) that teach healthy weight management strategies. This study might suit individuals with atrial fibrillation, classified as obese, and leading a sedentary lifestyle. As an unphased trial, it offers a unique opportunity to explore innovative strategies for improving heart health and weight management.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently taking GLP-1 receptor agonists.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that behavioral weight loss programs and cardiac rehabilitation are safe for individuals. These treatments aid in weight loss and enhance heart health without causing major issues.
Behavioral weight loss programs use group classes to change thoughts and behaviors for weight loss. Studies have found that patients tolerate this method well, with no serious side effects.
Cardiac rehabilitation includes exercise sessions supervised by health professionals and is also safe. Research indicates it can help with heart rhythm problems like atrial fibrillation and improve fitness without increasing health risks.
Overall, both behavioral weight loss programs and cardiac rehabilitation are safe options for improving heart health and losing weight.12345Why are researchers excited about this trial?
Researchers are excited about the combination of Behavioral Weight Loss Intervention (BWLT) and Cardiac Rehab (CR) for people with atrial fibrillation and obesity because it takes a unique approach by integrating weight management directly into cardiac rehabilitation. Unlike standard cardiac rehab programs that focus mainly on improving cardiovascular fitness, this new method adds weekly behavioral weight loss classes, aiming to address obesity as a key factor in overall heart health. This dual-focus strategy could potentially enhance the effectiveness of cardiac rehab by simultaneously tackling weight loss, which may improve atrial fibrillation management and overall patient outcomes.
What evidence suggests that this trial's treatments could be effective for atrial fibrillation and obesity?
Research shows that losing weight can help manage symptoms of atrial fibrillation (AF), a heart condition. People with obesity who lose about 10% of their body weight often experience fewer AF symptoms. In this trial, participants in the intervention arm will join a behavioral weight loss program combined with cardiac rehab. Studies have shown that this combination helps patients lose more weight than cardiac rehab alone. Another study suggested that this approach can also reduce the impact of AF. Overall, losing weight through these methods may improve heart rhythm and ease AF symptoms.12367
Who Is on the Research Team?
Tavis Campbell, PhD
Principal Investigator
University of Calgary
Are You a Good Fit for This Trial?
This trial is for adults over 18 with atrial fibrillation or flutter and obesity (BMI ≥30), leading a sedentary lifestyle. They must speak English and be open to weight loss treatment, but can't have done similar programs or had bariatric surgery recently, nor should they have uncontrolled heart issues or be on certain medications.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants engage in a 12-week outpatient cardiac rehabilitation program with or without additional weekly behavioural weight loss classes
Follow-up
Participants are monitored for weight loss, AF burden, and other health outcomes
Long-term Follow-up
Participants' weight loss and AF symptoms are assessed at 52 weeks post-randomization
What Are the Treatments Tested in This Trial?
Interventions
- BWLT
- CR
BWLT is already approved in Canada, United States for the following indications:
- Weight loss in patients with atrial fibrillation and obesity
- Weight management in cardiac rehabilitation settings
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Calgary
Lead Sponsor
Alberta Health services
Collaborator
University of British Columbia
Collaborator